Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas

Clinical trial NCT01732913 · TERMINATED

Trial details

NCT number: NCT01732913
Sponsor: Gilead Sciences
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Indolent Non-Hodgkin's Lymphomas

Start date: 2013-01-16
Primary completion: 2016-05-18
Enrollment: 295

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.